A5020390236- Protein Degradation and Inhibitors
- Multiple Myeloma Research and Treatments
- Ubiquitin and proteasome pathways
- CAR-T cell therapy research
- Sarcoma Diagnosis and Treatment
- Cancer-related gene regulation
- Signaling Pathways in Disease
Harvard University
2018-2025
Dana-Farber Cancer Institute
2018-2025
Ewing sarcoma is a pediatric cancer driven by EWS-ETS transcription factor fusion oncoproteins in an otherwise stable genomic background. The majority of tumors express wild-type TP53, and thus, therapies targeting the p53 pathway would benefit most patients. To discover targets specific for TP53 sarcoma, we used genome-scale CRISPR-Cas9 screening approach identified validated MDM2, MDM4, USP7, PPM1D as druggable dependencies. stapled peptide inhibitor MDM2 ATSP-7041, showed anti-tumor...
Advancements in the treatment of multiple myeloma (MM) have resulted an improvement survival rate. However, there continues to be urgent need for improved therapies. The protein arginine methyltransferase, CARM1 (coactivator associated methyltransferase 1), is emerging as a potential cancer therapy target and inhibitors been developed. MM cell lines are particularly dependent on survival. Here, we show that targeting through small molecule inhibition potentiates activity immunomodulatory...